Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10494053 | 0.90 | STAT3 (0.45) | RAB9ANPC1HPGDSMN1; SMN2STAT3 | |
| SCHEMBL14966802 | 0.88 | STAT3 (0.39) | RAB9ANPC1HPGDSMN1; SMN2STAT3 | |
| SCHEMBL1018458 | 0.87 | TSHR (0.50) | RAB9ANPC1HPGDSMN1; SMN2STAT3 | |
| SCHEMBL18398074 | 0.87 | HDAC8 (0.43) | ESRRASMN1; SMN2STAT3MAPTCA12 | |
| SCHEMBL1017951 | 0.86 | PDK1 (0.49) | RAB9ANPC1HPGDSMN1; SMN2STAT3 | |
| SCHEMBL14721706 | 0.83 | CA12 (0.40) | ESRRARAB9ANPC1HPGDMAPT | |
| SCHEMBL1020385 | 0.83 | AURKA (0.43) | RAB9ANPC1HPGDSMN1; SMN2STAT3 | |
| SCHEMBL5781341 | 0.83 | KDM4E (0.49) | RAB9AHPGDSMN1; SMN2STAT3L3MBTL1 | |
| SCHEMBL3843873 | 0.81 | NR1H4 (0.54) | RAB9ANPC1HPGDSMN1; SMN2CASP3 | |
| SCHEMBL3116280 | 0.81 | MAPT (0.50) | RAB9ANPC1HPGDSMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017016883-A1 | PROCESS FOR PREPARATION OF CYCLOPENTENE COMPOUNDS | BASF SE (DE) | 2017-02-02 | — | — | WO | disclosed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | GENENTECH, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | VCAM1, CD58, ITGB8 | ESRRA 2007/4885RAB9A 969/4885NPC1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.